Keratitis Pipeline Review H1 2017 report provides comprehensive information on the Keratitis
therapeutics under development complete with analysis by stage of development, Keratitis drug
target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report
also covers the descriptive pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the report provides an
overview of key players involved in therapeutic development for Keratitis and features dormant and
discontinued projects.
Inquire more on this Research Report at
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1001424
Key Companies Involved In Keratitis Therapeutics Development Analysed In Report: Adamis
Pharmaceuticals Corp, Dompe Farmaceutici SpA, Editas Medicine Inc, EyeGate Pharmaceuticals Inc,
NanoViricides Inc, RegeneRx Biopharmaceuticals Inc, SIFI SpA, and the Medicines Company
Keratitis Drug Profiles Discussed In Report: Acyclovir sodium, B-2088, C-31G, cenegermin,
Herpecide, IBN-1, JDE-004, KU-55933, PIM-45, polihexanide, RGN-259, targocil, tigecycline
Keratitis Therapeutics Pipeline guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I,
Preclinical and Discovery stages are 1, 2, 3, 17 and 1 respectively. Similarly, the Universities portfolio
in Preclinical and Discovery stages comprises 5 and 1 molecules; Bronchiectasis pipeline guide helps
in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Get Discount on Keratitis Pipeline Review Report 2017@
http://www.reportsnreports.com/contacts/discount.aspx?name=1001424 (This report is available
at upto 25% Discount till June 02nd 2017.)
The guide is built using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC filings, investor presentations
and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are
captured on a real time basis.
Scope
The report provides a snapshot of the global therapeutic landscape of Keratitis. The report reviews
pipeline therapeutics for Keratitis by companies and universities/research institutes based on
information derived from company and industry-specific sources. The report covers pipeline
products based on various stages of development ranging from pre-registration till discovery and
undisclosed stages. The report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other
developmental activities. The report reviews key player’s involved Keratitis therapeutics and enlists
all their major and minor projects. The report assesses Keratitis therapeutics based on drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The report
summarizes all the dormant and discontinued pipeline projects. The report reviews latest news
related to pipeline therapeutics for Keratitis